目的 探讨度拉糖肽治疗肥胖2型糖尿病对血糖水平及体格检查指标的影响.方法 52例肥胖 2 型糖尿病患者,以随机数字表法分为对照组及观察组,各 26 例.对照组采用调整生活方式、二甲双胍治疗,观察组在对照组的基础上联合度拉糖肽治疗.比较两组患者的体格检查指标[体重、体质量指数(BMI)],胰岛素分泌功能指标[空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、胰岛素分泌指数(HOMA-β)],血糖指标[空腹血糖(FPG)、餐后 2 h血糖(2 h PG)及糖化血糖蛋白(HbA1c)],不良反应发生情况.结果 与治疗前对比,两组治疗后体重、BMI均降低,且观察组体重(60.05±2.85)kg、BMI(23.36±1.11)kg/m2 低于对照组的(67.85±3.11)kg、(25.68±1.19)kg/m2(P<0.05).与治疗前对比,两组治疗后血清FINS、HOMA-IR均降低,HOMA-β均升高;且观察组FINS(15.49±2.16)μU/L、HOMA-IR(2.44±0.85)低于对照组的(21.95±3.25)μU/L、(5.26±1.16),HOMA-β(51.14±3.36)高于对照组的(42.01±2.52)(P<0.05).与治疗前对比,两组治疗后血清FPG、2 h PG、HbA1c水平均降低;且观察组FPG(5.59±0.53)mmol/L、2 h PG(7.05±0.54)mmol/L、HbA1c(5.95±0.21)%低于对照组的(8.38±0.87)mmol/L、(11.72±0.61)mmol/L、(8.22±0.36)%(P<0.05).治疗期间两组患者的不良反应发生率对比,差异无统计学意义(P>0.05).结论 肥胖 2 型糖尿病患者应用度拉糖肽能有效的降低患者的血糖水平以及体重,改善其胰岛素分泌功能,且具有较高的安全性.
Effect of dulaglutide in the treatment of obese type 2 diabetes mellitus on blood glucose level and physical examination indexes
Objective To explore the effect of dulaglutide in the treatment of obese type 2 diabetes mellitus on blood glucose level and physical examination indexes.Methods A total of 52 patients with obese type 2 diabetes mellitus were divided into a control group and an observation group according to the random numerical table,with 26 cases in each group.The control group was treated with lifestyle adjustment and metformin,while the observation group was treated with dulaglutide on the basis of the control group.Patients in both groups were compared in terms of physical examination indexes[body weight and body mass index(BMI)],insulin secretion function index[fasting insulin(FINS),Homoeostasis model assessment of insulin resistance(HOMA-IR),Homoeostasis model assessment of β cell function(HOMA-β)],blood glucose index[fasting plasma glucose(FPG),2 h postprandial glucose(2 h PG),glycated glycoprotein(HbA1c)],and the occurrence of adverse reactions.Results Compared with before treatment,the body weight and BMI in both groups decreased after treatment;after treatment,the observation group had body weight of(60.05±2.85)kg and BMI of(23.36±1.11)kg/m2,which were lower than(67.85±3.11)kg and(25.68±1.19)kg/m2 in the control group(P<0.05).Compared with before treatment,the serum FINS and HOMA-IR decreased and HOMA-β increased in both groups after treatment;after treatment,the observation group had FINS of(15.49±2.16)μU/L and HOMA-IR of(2.44±0.85),which were lower than(21.95±3.25)μU/L and(5.26±1.16)in the control group;the observation group had higher HOMA-β of(51.14±3.36)than(42.01±2.52)in the control group(P<0.05).Compared with before treatment,the serum levels of FPG,2 h PG and HbA1c decreased in both groups after treatment;after treatment,the observation group had FPG of(5.59±0.53)mmol/L,2 h PG of(7.05±0.54)mmol/L and HbA1c of(5.95±0.21)%,which were lower than(8.38±0.87)mmol/L,(11.72±0.61)mmol/L and(8.22±0.36)%in the control group(P<0.05).During treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The application of dulaglutide in the treatment of obese type 2 diabetes mellitus can effectively reduce the blood glucose level and body weight of patients,improve the insulin secretion function,and has high safety.
Type 2 diabetes mellitusObesityDulaglutideBlood glucosePhysical examination
万方数据
维普
